NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, News & Analysis

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals Inc (NASDAQ:ANIP) released its quarterly earnings data on Wednesday, August, 7th. The specialty pharmaceutical company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.18 by $0.26. The specialty pharmaceutical company had revenue of $54.36 million for the quarter, compared to the consensus estimate of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. ANI Pharmaceuticals's quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the business posted $1.13 EPS. View ANI Pharmaceuticals' Earnings History.

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for ANI Pharmaceuticals.

ANI Pharmaceuticals issued an update on its FY19 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of $5.57-6.21 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.01. The company issued revenue guidance of $220-226 million, compared to the consensus revenue estimate of $239.80 million.

4 brokers have issued 12-month target prices for ANI Pharmaceuticals' shares. Their forecasts range from $76.00 to $90.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $84.25 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.

Press coverage about ANIP stock has trended negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for ANI Pharmaceuticals.

ANI Pharmaceuticals saw a decrease in short interest in August. As of August 31st, there was short interest totalling 1,393,100 shares, a decrease of 6.7% from the July 31st total of 1,493,700 shares. Based on an average daily trading volume, of 162,000 shares, the days-to-cover ratio is currently 8.6 days. Approximately 15.2% of the shares of the stock are sold short. View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include Nektar Therapeutics (NKTR), Evotec (EVTCY), Mirati Therapeutics (MRTX), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), HUTCHISON CHINA/S (HCM), Arena Pharmaceuticals (ARNA), Reata Pharmaceuticals (RETA), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Alibaba Group (BABA), Broadcom (AVGO), Celgene (CELG), NVIDIA (NVDA), Cisco Systems (CSCO) and NXP Semiconductors (NXPI).

ANI Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.82%), Vanguard Group Inc. (4.68%), Nomura Holdings Inc. (3.12%), Nomura Holdings Inc. (3.10%), First Manhattan Co. (2.44%) and Renaissance Technologies LLC (2.39%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Weiss Asset Management LP, Charles Schwab Investment Management Inc., Cadence Capital Management LLC, Panagora Asset Management Inc., Skandinaviska Enskilda Banken AB publ, Phocas Financial Corp. and Phocas Financial Corp.. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

ANIP stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., Nomura Holdings Inc., Nomura Holdings Inc., Renaissance Technologies LLC, Nuveen Asset Management LLC, BlackRock Inc., THB Asset Management and First Manhattan Co.. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $73.09.

ANI Pharmaceuticals has a market capitalization of $884.39 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.

The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com/.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]